Lung Cancer Associated With Cystic Airspaces · Observational Study

Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces

ClinicalTrials.gov · September 4, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a clinical trial registry record describing a planned observational study of tumor staging methods in lung cancer with cystic airspaces. No results are posted; the record outlines research questions and planned outcome measures (disease-free survival and overall survival over 5 years) but contains no efficacy or prognostic data.

What was studied

Observational. Lung Cancer Associated With Cystic Airspaces. Intervention: group 1; group 2; group 3. n = 500. 1 site: China.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registry record for an ongoing observational study with no results posted; it describes planned enrollment and research questions rather than evidence.

Study design

As stated by the source record.

MethodsCohort model. Prospective time perspective. Primary outcome measures: DFS (assessed at From enrollment to the end of surgery for 5 years); OS (assessed at From enrollment to the end of surgery for 5 years)

DesignObservational

PopulationLung Cancer Associated With Cystic Airspaces

Sample size500

Interventiongroup 1; group 2; group 3

Setting1 site: China

Reported figures

Quoted from the source exactly as published.

Planned enrollment500

Primary outcome measure 1DFS (disease-free survival), from enrollment to end of surgery, 5-year follow-up

Primary outcome measure 2OS (overall survival), from enrollment to end of surgery, 5-year follow-up

Study typeObservational

Caveats

This is a registry record only; no results are posted or available for analysis.
Study is still recruiting; follow-up data (5 years of DFS and OS) not yet available.
No description of staging methods being compared or specific imaging protocols to be used.
No statistical analysis plan, interim efficacy, or comparator arm disclosed in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational design; no control group or randomization specified.

Directness

insufficient

No results reported; clinical outcomes (DFS, OS) are planned but not yet measured.

Consistency

insufficient

Single-center study; no comparative data available to assess consistency.

Risk of bias

insufficient

Registry record does not describe blinding, allocation concealment, or analytical approach.

Sample adequacy

moderate

Planned enrollment 500 participants; adequate for observational registry, follow-up status unknown.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07066813). This is a study registration, not published results. Lead sponsor: Central South University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 500 participants (ESTIMATED). Conditions: Lung Cancer Associated With Cystic Airspaces. Primary outcome measures: DFS , From enrollment to the end of surgery for 5 years; OS , From enrollment to the end of surgery for 5 years. Brief summary: The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT07066813Lung Cancer Associated With Cystic AirspacesCentral South University